Genocea Biosciences (NASDAQ: GNCA) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Genocea Biosciences to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, dividends, earnings, valuation and risk.
Insider & Institutional Ownership
34.7% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.7% of Genocea Biosciences shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a summary of recent recommendations for Genocea Biosciences and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Genocea Biosciences Competitors||662||2507||6638||135||2.63|
Genocea Biosciences currently has a consensus target price of $7.38, suggesting a potential upside of 555.56%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 9.91%. Given Genocea Biosciences’ higher possible upside, equities research analysts clearly believe Genocea Biosciences is more favorable than its competitors.
This table compares Genocea Biosciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Genocea Biosciences Competitors||-4,131.66%||-30.74%||-38.09%|
Earnings and Valuation
This table compares Genocea Biosciences and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Genocea Biosciences||$230,000.00||-$49.57 million||-0.52|
|Genocea Biosciences Competitors||$217.40 million||-$39.40 million||-59.83|
Genocea Biosciences’ competitors have higher revenue and earnings than Genocea Biosciences. Genocea Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Genocea Biosciences has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, Genocea Biosciences’ competitors have a beta of 1.48, meaning that their average share price is 48% more volatile than the S&P 500.
Genocea Biosciences competitors beat Genocea Biosciences on 9 of the 13 factors compared.
About Genocea Biosciences
Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual’s tumor.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.